S-Ruxolitinib, also known as INCB018424 or INCB-018424, is a small molecule inhibitor of Janus kinase (JAK) 1 and JAK 2. This product is a white to off-white powder with the chemical formula C17H18N6O and a molecular weight of 306.37 g/mol. Its CAS number is 941685-37-6.
Top ten keywords from Google and synonyms
Health benefits of S-Ruxolitinib
S-Ruxolitinib has shown potential health benefits in various areas such as myelofibrosis, polycythemia vera, and immune disorders.
Myelofibrosis and Polycythemia Vera: S-Ruxolitinib has been FDA-approved for the treatment of intermediate or high-risk myelofibrosis and polycythemia vera. These are rare blood cancers characterized by abnormal red blood cell production and bone marrow fibrosis. S-Ruxolitinib inhibits JAK1 and JAK2, which are involved in the signaling pathways that lead to inflammation and cell proliferation. By inhibiting these pathways, S-Ruxolitinib reduces the symptoms associated with these diseases, such as fatigue, spleen enlargement, and night sweats.
Immune Disorders: S-Ruxolitinib has also shown promise in the treatment of immune disorders such as rheumatoid arthritis and inflammatory bowel disease. The inhibition of JAK1 and JAK2 leads to a reduction in inflammation, which is a key contributor to the pathogenesis of these diseases.
S-Ruxolitinib has shown potential as a therapeutic agent in the treatment of myelofibrosis, polycythemia vera, and immune disorders such as rheumatoid arthritis and inflammatory bowel disease.
As an inhibitor of JAK1 and JAK2, S-Ruxolitinib blocks a signaling pathway that leads to inflammation and cell proliferation. By inhibiting this pathway, it reduces the symptoms associated with myelofibrosis, polycythemia vera, and immune disorders.
While S-Ruxolitinib has shown promising results in clinical trials, further investigation into its safety in humans is required. Animal studies have not shown significant adverse effects, but more research is needed to fully understand its safety profile.
The most common side effects associated with S-Ruxolitinib include anemia, thrombocytopenia (low platelet count), and infection. Less common side effects include dizziness, headache, and gastrointestinal upset.
S-Ruxolitinib dosing information varies depending on the condition being treated. Patients should consult with their healthcare provider for specific dosing guidelines.
S-Ruxolitinib has shown significant potential as a therapeutic agent in various fields of medicine, particularly in the treatment of myelofibrosis, polycythemia vera, and immune disorders such as rheumatoid arthritis and inflammatory bowel disease. Its mechanism of action in inhibiting JAK1 and JAK2 provides a novel approach to reducing inflammation and cell proliferation, which are key contributors to the pathogenesis of these diseases. While more research is needed to establish safety and dosing guidelines for human use, S-Ruxolitinib shows promise as a potential treatment option